HC Wainwright Has Lowered Expectations for Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target decreased by analysts at HC Wainwright from $12.00 to $11.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 46.47% from the company’s current price. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q2 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.21) EPS and FY2030 earnings at $0.17 EPS.

EPRX has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Cantor Fitzgerald raised their target price on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Finally, Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eupraxia Pharmaceuticals presently has an average rating of “Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Trading Down 0.9%

Shares of EPRX opened at $7.51 on Tuesday. Eupraxia Pharmaceuticals has a 12-month low of $2.68 and a 12-month high of $9.32. The firm has a market capitalization of $270.06 million, a P/E ratio of -7.29 and a beta of 1.27. The firm has a 50-day moving average price of $8.30 and a 200 day moving average price of $6.87.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). Equities research analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new stake in Eupraxia Pharmaceuticals during the 3rd quarter worth about $7,965,000. Ally Bridge Group NY LLC acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $5,398,000. Ikarian Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at about $4,606,000. Squadron Capital Management LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at about $3,775,000. Finally, Velan Capital Investment Management LP acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter worth about $2,077,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.